Interview with Richard de Souza, CEO, Martindale Pharma
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
Address: Hubert Road
Brentwood
Essex CM14 4JY
,United Kingdom
Tel: +44 (0) 1277 266 600
Web: http://www.martindalepharma.co.uk/
After starting out as a London chemist store owned by William Martindale, Martindale Pharma has remained in business for more than a century. The company’s reputation as a leading UK manufacturer and supplier of specialty prescription pharmaceutical products for healthcare professionals, working in both Primary and Secondary Care, has grown steadily over that time. Martindale Pharma is now firmly established as a leading supplier to the UK’s NHS and exports its products to a number of other major pharmaceutical markets. Martindale Pharma has a clearly defined mission: to provide medicines to improve the quality of people’s lives.
Martindale Pharma has built strong relationships with prescribers and influencers on drug choice in its chosen business segments (see below). Working on the basis of a partnership, Martindale Pharma has also built a strong relationship with healthcare service providers such as Alliance Boots, Celesio, AAH, Lloyds, Co-Operative Pharmacies, as well as the NHS. Our operating philosophy is one of close co-operation and responsiveness to customer needs.
Key Business Segments:
Addiction
Martindale Pharma is ranked number one in market share in the opiate addiction market, driven by the success of our brand Physeptone, the UK’s leading methadone product. We work in partnership with the NHS, Community Drug Teams, third party providers of addiction services as well as retail pharmacies to ensure that drug service users receive the optimum support as they seek to move away from the use of illicit opiates.
Critical Care
Martindale Pharma manufacture and market the Aurum Range, the UK’s leading range of 11 pre-filled syringes for emergency use by resuscitation and operating theatre teams. We also manufacture and market a Caffeine product for treatment of Apnoea of Prematurity a critical care area in neonatology.
Specials
Martindale Pharma can manufacture over 30,000 products in a range of formulations. Handling around 700-800 individual orders a day for these highly personalised medicines, the majority of products are made by our dedicated team of pharmacists and technical staff. Over 90% of orders are supplied to the customer within 24 hours of ordering. Martindale Pharma is ranked number one by market share in this segment.
Ophthalmics
Martindale Pharma provides a broad range of ophthalmic products as generic, own label and third party brands. We are one of the top three companies in our chosen Ophthalmics disease segments.
Hospital Speciality Products
Martindale Pharma’s range of principally parenteral products are used in a wide range of hospital situations. We are one of the country’s leading manufacturers of sterile injection products supplying over 25 million ampoules a year.
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
Liam O’Toole, CEO of Arthritis Research UK, discusses how arthritis impacts the British economy, raising public awareness of the condition, the potential ramifications of Brexit, and the importance of inter-stakeholder…
Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls…
Sir Robert Lechler, president of the Academy of Medical Sciences (AMS), discusses the Academy’s role in promoting medical research in the UK and how that stands to change in the…
Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with…
Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the…
Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why…
Tony Jones, CEO of One Nucleus, a life sciences membership organization centered on the Greater London-Cambridge-East of England corridor, discusses the role of SMEs within the UK’s healthcare ecosystem, translational…
Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life…
Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can…
Sir John Chisholm, executive chair of Genomics England – a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to…
Aisling Burnand, CEO of the Association of Medical Research Charities (AMRC), shares the organization’s vision and the significant contributions of its member charities to the life sciences R&D ecosystem in…
See our Cookie Privacy Policy Here